Medigene Ag Stock Fundamentals
| MDGEFDelisted Stock | USD 2.59 0.00 0.00% |
Medigene AG fundamentals help investors to digest information that contributes to Medigene's financial success or failures. It also enables traders to predict the movement of Medigene Pink Sheet. The fundamental analysis module provides a way to measure Medigene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medigene pink sheet.
Medigene |
Medigene AG Company Return On Asset Analysis
Medigene's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Medigene Return On Asset | 0.0887 |
Most of Medigene's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medigene AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Medigene AG has a Return On Asset of 0.0887. This is 101.01% lower than that of the Healthcare sector and 100.38% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 163.36% lower than that of the firm.
Medigene AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medigene's current stock value. Our valuation model uses many indicators to compare Medigene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medigene competition to find correlations between indicators driving Medigene's intrinsic value. More Info.Medigene AG is regarded fourth in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Medigene AG is roughly 1.99 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medigene's earnings, one of the primary drivers of an investment's value.Medigene Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medigene's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Medigene could also be used in its relative valuation, which is a method of valuing Medigene by comparing valuation metrics of similar companies.Medigene is currently under evaluation in return on asset category among its peers.
Medigene Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0887 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 30.5 M | |||
| Shares Outstanding | 24.56 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 4.62 % | |||
| Price To Earning | 5.26 X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 1.86 X | |||
| Revenue | 10.46 M | |||
| Gross Profit | 9.1 M | |||
| EBITDA | (6.49 M) | |||
| Net Income | (9.98 M) | |||
| Cash And Equivalents | 39.38 M | |||
| Cash Per Share | 1.60 X | |||
| Total Debt | 3.73 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 6.04 X | |||
| Book Value Per Share | 2.41 X | |||
| Cash Flow From Operations | (10.75 M) | |||
| Earnings Per Share | 0.42 X | |||
| Price To Earnings To Growth | (0.36) X | |||
| Target Price | 18.82 | |||
| Number Of Employees | 61 | |||
| Beta | 0.88 | |||
| Market Capitalization | 56.49 M | |||
| Total Asset | 59.47 M | |||
| Z Score | 9.0 | |||
| Net Asset | 59.47 M |
About Medigene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medigene AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medigene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medigene AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company was founded in 1994 and is headquartered in Munich, Germany. Medigene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 61 people.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Medigene Pink Sheet
If you are still planning to invest in Medigene AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigene's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |